Somatostatin Analogues are medications used to treat certain types of tumors, including neuroendocrine tumors. They work by mimicking a natural hormone in the body called somatostatin, which helps to slow down the growth of these tumors. In this trial, the role of somatostatin analogues is to see if continuing their use can help patients live longer without their disease getting worse.

PRRT (Peptide Receptor Radionuclide Therapy) is a type of targeted therapy used to treat neuroendocrine tumors. It involves using a small amount of radioactive material that is attached to a molecule that specifically targets tumor cells. This allows the radiation to be delivered directly to the tumor, helping to shrink it or slow its growth. In this trial, PRRT is being used as a second-line treatment to see how it affects the progression of the disease.

Targeted Therapy refers to a group of medications that specifically target certain molecules involved in the growth and spread of cancer cells. These therapies are designed to interfere with the cancer’s ability to grow and spread, while causing less harm to normal cells. In this trial, targeted therapy is being used as a second-line treatment to evaluate its effectiveness in slowing down the disease progression in patients with neuroendocrine tumors.

Neuroendocrine Tumors – Neuroendocrine tumors are a diverse group of neoplasms that originate from neuroendocrine cells, which are found throughout the body. These tumors can produce hormones, leading to various symptoms depending on the hormones released. They often grow slowly, but their progression can vary significantly, with some remaining indolent for years while others may grow more rapidly. As they progress, neuroendocrine tumors can metastasize to other parts of the body, most commonly the liver. The symptoms and progression depend on the tumor’s location, size, and whether it secretes hormones. Over time, they may cause complications related to hormone overproduction or mass effect on surrounding tissues.